Skip to main content
PMC home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 1988;24(3):320–325. doi: 10.1007/BF02028289

Extracellular phospholipase A2: causative agent in circulatory collapse of septic shock?

P Vadas 1,2, W Pruzanski 1,2, E Stefanski 1,2
PMCID: PMC7096008  PMID: 3177094

The content is available as a PDF (529.0 KB).

Footnotes

Supported by The Arthritis Society and The Wellesley Hospital Research Institute.

References

  • [1].Kreger B. E., Craven D. E., Carling P. C., McCabe W. R. Gram-negative bacteremia. Reassessment of etiology, epidemiology and ecology in 612 patients. Am. J. Med. 1980;68:332–343. doi: 10.1016/0002-9343(80)90101-1. [DOI] [PubMed] [Google Scholar]
  • [2].Zimmerman J. J., Dietrich K. A. Current perspectives on septic shock. Pediatr. Clin. North Am. 1987;34:131–163. doi: 10.1016/s0031-3955(16)36186-7. [DOI] [PubMed] [Google Scholar]
  • [3].Sprung C. L., Caralis P. V., Marcial E. H., et al. The effects of high-dose corticosteroids in patients with septic shock. N. Engl. J. Med. 1984;311:1137–1143. doi: 10.1056/NEJM198411013111801. [DOI] [PubMed] [Google Scholar]
  • [4].Tracey K. J., Beutler B., Lowry S. F., Merryweather J., et al. Shock and tissue injury induced by recombinant human cachectin. Science. 1986;234:470–474. doi: 10.1126/science.3764421. [DOI] [PubMed] [Google Scholar]
  • [5].Wilson M. F., Brackett D. J. Release of vasoactive hormones and circulatory changes in shock. Circ. Shock. 1983;11:225–234. [PubMed] [Google Scholar]
  • [6].Lefer A. M. Eicosanoids as mediators of ischemia and shock. Federation Proc. 1985;44:275–280. [PubMed] [Google Scholar]
  • [7].Vadas P., Wasi S., Movat H., Hay J. Extracellular phospholipase A2 mediates inflammatory hyperemia. Nature. 1981;273:583–585. doi: 10.1038/293583a0. [DOI] [PubMed] [Google Scholar]
  • [8].Vadas P., Hay J. The appearance and significance of phospholipase A2 in lymph draining tuberculin reactions. Am. J. Pathol. 1982;107:285–291. [PMC free article] [PubMed] [Google Scholar]
  • [9].Vadas P., Pruzanski W. Role of extracellular phospholipase A2 in inflammation. Adv. Inflamm. Res. 1984;7:51–59. [Google Scholar]
  • [10].Franson R., Dobrow R., Weiss J., Elsbach P., Weglicki W. B. Isolation and characterization of a phospholipase A2 from an inflammatory exudate. J. Lipid Res. 1978;19:18–23. [PubMed] [Google Scholar]
  • [11].Pruzanski W., Vadas P., Stefanski E., Urowitz M. B. Phospholipase A2 activity in sera and synovial fluids in rheumatoid arthritis and osteoarthritis: its possible role as a proinflammatory enzyme. J. Rheumatol. 1986;12:211–216. [PubMed] [Google Scholar]
  • [12].Vadas P., Stefanski E., Pruzanski W. Characterization of extracellular phospholipase A2 in rheumatoid synovial fluid. Life Sci. 1985;36:579–587. doi: 10.1016/0024-3205(85)90640-X. [DOI] [PubMed] [Google Scholar]
  • [13].Stefanski E., Pruzanski W., Sternby B., Vadas P. Purification of a soluble phospholipase A2 from synovial fluid in rheumatoid arthritis. J. Biochem. 1986;100:1297–1303. doi: 10.1093/oxfordjournals.jbchem.a121836. [DOI] [PubMed] [Google Scholar]
  • [14].W. Pruzanski, E. Keystone and P. Vadas,Serum phospholipase A2levels correlate with disease activity in rheumatoid arthritis. Clin. Exp. Immunol., (submitted). [PubMed]
  • [15].Vadas P. The efficacy of anti-inflammatory agents with respect to extracellular phospholipase A2 activity. Life Sci. 1982;30:155–162. doi: 10.1016/0024-3205(82)90647-6. [DOI] [PubMed] [Google Scholar]
  • [16].Vadas P., Pruzanski W., Sos A., Melcher A., Jacobs H., Cheong T. Synthesis and secretion of soluble phospholipase A2 from cultured osteoblasts. Arthr. Rheum. 1987;30(suppl):65. [Google Scholar]
  • [17].Chang J., Gilman S., Lewis A. Interleukin 1 activates phospholipase A2 in rabbit chondrocytes: a possible signal for IL-1 action. J. Immunol. 1986;136:1283–1287. [PubMed] [Google Scholar]
  • [18].Pruzanski W., Vadas P., Fornasier V. Inflammatory effect of intradermal administration of soluble phospholipase A2 in rabbits. J. Invest. Dermatol. 1986;86:380–383. doi: 10.1111/1523-1747.ep12285639. [DOI] [PubMed] [Google Scholar]
  • [19].Vadas P., Hay J. Secretion of a hyperemia-inducing moiety by mitogen or glycogen-stimulated mononuclear inflammatory cells of sheep and rabbit. Int. Arch. Allergy appl. Immunol. 1980;62:142–151. doi: 10.1159/000232506. [DOI] [PubMed] [Google Scholar]
  • [20].Vadas P., Hay J. Cutaneous blood flow measurements: a standardization of the microsphere assay for yasocative agents. Agents and Actions. 1978;8:504–508. doi: 10.1007/BF02111437. [DOI] [PubMed] [Google Scholar]
  • [21].Shubin H., Weil M.-H. Bacterial shock. JAMA. 1976;235:421–424. doi: 10.1001/jama.235.4.421. [DOI] [PubMed] [Google Scholar]
  • [22].Urbaschek B., Urbaschek R. The inflammatory response of endotoxins. Bibl. Ant. 1979;17:74–104. [PubMed] [Google Scholar]
  • [23].Vadas P., Hay J. Invovlement of circulating phospholipase A2 in the pathogenesis of hemodynamic changes in endotoxin shock. Can. J. Physiol. Pharmacol. 1983;61:561–566. doi: 10.1139/y83-086. [DOI] [PubMed] [Google Scholar]
  • [24].Hallman M., Spragg R., Harrell J. H., Moser K. M., Gluck L. Evidence of lung surfactant abnormality in respiratory failure. J. Clin. Invest. 1982;70:673–683. doi: 10.1172/JCI110662. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [25].Vadas P. Elevated plasma phospholipase A2 levels: correlation with the hemodynamic and pulmonary changes in gram-negative septic shock. J. Lab. Clin. Med. 1984;104:873–881. [PubMed] [Google Scholar]
  • [26].P. Vadas, W. Pruzanski, E. Stefanski, B. Sternby, R. Mustard, J. Bohnen, I. Fraser, V. Farewell and C. Bombardier,The pathogenesis of hypotension in septic shock: correlation of circulating phospholipase A2levels with circulatory collapse. Critical Care Med., in press. [DOI] [PubMed]
  • [27].Vadas P., Pruzanski W. Role of secretory phospholipases A2 in the pathobiology of disease. Laboratory Invest. 1986;55:391–404. [PubMed] [Google Scholar]
  • [28].Flower R. Macrocortin and the antiphospholipase proteins. Adv. Inflam. Res. 1984;8:1–34. [Google Scholar]
  • [29].P. Vadas, W. Pruzanski, E. Stefanski, J. Ruse, V. Farewell, J. McLaughlin and C. Bombardier,Concordance of endogenous cortisol and phospholipase A2levels in gram-negative septic shock, A prospective study. J. Lab. Clin. Med., in press. [PubMed]
  • [30].McCullagh P. Regression models for orindal data. J. Royal Statistical Society. 1980;142:109–142. [Google Scholar]
  • [31].Vadas P., Stefanski E., Pruzanski W. Comparative analysis of assays for phospholipase A2 activity using biomembrane associated and micellar substrates. The influence of albumin. Inflammation. 1986;10:183–193. doi: 10.1007/BF00916000. [DOI] [PubMed] [Google Scholar]
  • [32].Vadas P., Stefanski E., Pruzanski W. Potential therapeutic efficacy of inhibitors of human phospholipase A2 in septic shock. Agents and Actions. 1986;19:194–202. doi: 10.1007/BF01966206. [DOI] [PubMed] [Google Scholar]
  • [33].Vick J. A., Brooks R. B. Pharmacological studies of the major fractions of bee venom. Am. Bee J. 1972;112:288–289. [Google Scholar]
  • [34].Hebermann E. Beiträge zur pharmacologie von phospholipase. A. Arch. Exp. Pathol. Pharmakol. 1957;230:538–546. [PubMed] [Google Scholar]
  • [35].Marsh N. A., Whaler B. C. The effects of honey bee venom and two of its constituents, melittin and phospholipase A2, on the cardiovascular system of the rat. Toxicon. 1980;18:427–435. doi: 10.1016/0041-0101(80)90050-1. [DOI] [PubMed] [Google Scholar]
  • [36].Shakir K. M. M., O'Brian J. T., Gartner S. L. Enhanced phospholipase A2 activity in rat plasma, liver and intestinal mucosa following endotoxin treatment: possible explanation for the protective effect of indomethacin in endotoxic shock. Metabolism. 1985;34:176–182. doi: 10.1016/0026-0495(85)90129-5. [DOI] [PubMed] [Google Scholar]
  • [37].Schmidt D., Hoffmann G. E. Activity of phospholipase A compared in serum of patients with pancreatic and nonpancreatic diseases. Clin. Chem. 1987;33:594–596. [PubMed] [Google Scholar]
  • [38].Flynn J. T., Henry J. M., Perkoswki W. Phospholipase A2 stimulated release of prostanoids from the isolated perfused rabbit liver: implications in regional cellular injury. Can. J. Physiol. Pharmacol. 1981;59:1268–1273. doi: 10.1139/y81-198. [DOI] [PubMed] [Google Scholar]
  • [39].Huang H. C. Effects of phospholipases A2 from Vipera russelli snake venom on blood pressure, plasma prostacyclin level, and renin activity in rats. Toxicon. 1984;22:253–264. doi: 10.1016/0041-0101(84)90026-6. [DOI] [PubMed] [Google Scholar]
  • [40].Ho C. L., Lee C. Y. Cardiovascular effects of phospholipases A2 purified from various snake venoms. Proc. Natl. Sci. Counc. B. ROC. 1981;5:181–189. [Google Scholar]
  • [41].Huang H. C. Release of slow-reacting substance from the guinea-pig lung by phospholipases A2 of Vipera russelli snake venom. Toxicon. 1984;22:359–372. doi: 10.1016/0041-0101(84)90080-1. [DOI] [PubMed] [Google Scholar]
  • [42].Hirata F., Schiffman E., Venkatasubramanian K., Solmon D., Axelrod J. A phospholipase A2 inhibitory protein in rabbit neutrophils induced by glucocorticoids. Proc. Natl. Acad. Sci. USA. 1980;77:2533–2536. doi: 10.1073/pnas.77.5.2533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [43].Blackwell G. J., Carnuccio R., DiRosa M., Flower R. J., Langham C. S. J., Parente L., Persico P., Russell-Smith N.-C., Stone D. Glucocorticoids induced the formation and release of anti-inflammatory and anti-phospholipase proteins into the peritoneal cavity of the rat. Br. J. Pharmacol. 1982;76:185–195. doi: 10.1111/j.1476-5381.1982.tb09205.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Agents and Actions are provided here courtesy of Nature Publishing Group

RESOURCES